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Ischemia is known to increase the deleterious effect of -amyloid (A), contributing to early cognitive impairment in Alzheimer’s
disease. Here, we investigated whether transient ischemia may function as a trigger for A-dependent synaptic impairment in the
entorhinal cortex (EC), acting through specific cellular signaling. We found that synaptic depression induced by oxygen glucose depri-
vation (OGD) was enhanced in EC slices either in presence of synthetic oligomeric A or in slices from mutant human amyloid precursor
protein transgenic mice (mhAPP J20). OGD-induced synaptic depression was ameliorated by functional suppression of RAGE. In partic-
ular, overexpression of the dominant-negative form of RAGE targeted to microglia (DNMSR) protects against OGD-induced synaptic
impairment in an amyloid-enriched environment, reducing the activation of stress-related kinases (p38MAPK and JNK) and the release
of IL-1. Our results demonstrate a prominent role for the RAGE-dependent neuroinflammatory pathway in the synaptic failure induced
by A and triggered by transient ischemia.
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Introduction
Alzheimer’s disease (AD), is increased by vascular pathologies
such as stroke or hypertension, suggesting common pathogenic
mechanisms closely related to ischemic injury (Girouard and Ia-
decola, 2006). In particular, -amyloid (A) overproduction,
which is believed to contribute to early impairment of cognitive
functions during AD, is triggered by ischemia. Indeed, hypoxia
modulates the expression and activity of A-metabolizing en-
zymes, resulting in increased A peptides, including the deleteri-
ous A(1-42) (Sun et al., 2006; Guglielmotto et al., 2009; Pluta et
al., 2013). Moreover, an increased susceptibility to ischemia has
been shown in the brains of amyloid precursor protein (APP)-
overexpressing mice (Zhang et al., 1997). However, a causal rela-
tionship between AD and brain ischemia at the molecular and
functional level has not been established.
Some evidence shows a progressive impairment of synaptic func-
tion with increasing extracellular A. In particular, synthetic oligo-
meric A(1-42) in the nanomolar range was shown to specifically
inhibit LTP in the hippocampus (Cullen et al., 1997; Lambert et al.,
1998; Vitolo et al., 2002; Walsh et al., 2002; Wang et al., 2004; Shan-
kar et al., 2008) and cortical areas (Origlia et al., 2008, 2009a),
whereas higher micromolar concentrations caused synaptic depres-
sion and LTD impairment (Snyder et al., 2005; Hsieh et al., 2006;
Parameshwaran et al., 2007; Origlia et al., 2010).
Interestingly, RAGE (Receptor for Advanced Glycation End-
products) expression changes in neuronal and non-neuronal
cells under ischemic conditions (Pichiule et al., 2007; Zhai et al.,
2008) and AD (Yan et al., 1996). RAGE is a receptor mediating
and focusing A effects on neuronal and non-neuronal cells (Yan
et al., 1995; Lue et al., 2001; Schmidt et al., 2001; Deane et al.,
2003), contributing to A-dependent functional impairment in
hippocampus (Arancio et al., 2004) and entorhinal cortex (EC;
Origlia et al., 2008, 2010). Moreover, inhibition of RAGE-
mediated transduction was shown to be effective in improving
cognition in APP/PS1 mice (Liu et al., 2014). However, whether
RAGE has a role in the development of neuronal impairment
following transient ischemia in AD is still unknown. We have
previously investigated the role of RAGE using transgenic mice
expressing a dominant-negative form of RAGE targeted to mi-
croglia (DNMSR) or neurons (DN-RAGE). We found that the
effect of nanomolar A on LTP is mediated by neuronal RAGE
activation of p38MAPK (Arancio et al., 2004; Origlia et al., 2008),
whereas LTD impairment and synaptic depression by micromo-
lar A involve the phosphorylation of p38MAPK and JNK, which
depend on microglial RAGE activation, along with the induction
of the proinflammatory cytokine IL-1 (Origlia et al., 2010).
Here, we investigated how RAGE expressed in different cell types
might contribute to A-dependent synaptic dysfunction occur-
ring under transient ischemia. Using in vitro oxygen/glucose de-
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privation (OGD; Tozzi et al., 2007; Medvedeva et al., 2009), we
found that increased extracellular amyloid resulting from either
exogenous supply of synthetic A(1-42) (Origlia et al., 2008,
2009a, 2010) or from transgenic expression of APP (Mucke et al.,
2000) facilitates synaptic depression induced by OGD in EC
slices. More importantly, overexpression of the dominant-
negative form of RAGE in microglia (DNMSR) protects against
OGD-induced synaptic impairment in an A-enriched environ-
ment by reducing the activation of p38MAPK and JNK and the
release of IL-1. Our results demonstrate a role for the RAGE-
dependent neuroinflammatory pathway in the synaptic failure
induced by A and triggered by ischemia.
Materials and Methods
Animals. Homozygous RAGE-null mice were generated and character-
ized as described previously (Origlia et al., 2008, 2010). Transgenic mice
with signal-transduction-deficient mutants of RAGE in which the cyto-
solic domain of the receptor has been deleted, thereby imparting a
dominant-negative RAGE effect, targeted to neurons (DN-RAGE, driven
by the platelet derived growth factor-B chain promoter) or to microglia
(DNMSR, driven by the macrophage scavenger receptor promoter), have
been used previously by our group (Arancio et al., 2004; Origlia et al.,
2008, 2010; Fang et al., 2010). Furthermore, mhAPP-transgenic mice
overexpressing an alternatively spliced human APP (hAPP) minigene
that encodes hAPP695, hAPP751, and hAPP770 bearing mutations linked to
familial AD (V717F, K670N/M671L) have been used (APPsweInd, line J20;
Mucke et al., 2000). Double-transgenic mice expressing DN-RAGE in
microglia and mhAPP were obtained by crossing DN-RAGE mice to
mhAPP mice as described previously (Fang et al., 2010). Male transgenic
mice and their littermate controls were used for the in vitro electrophys-
iology (age range, 2–3 months).
Pharmacological agents. A(1-42) and the reverse peptide, A(42-1),
were purchased from Abbiotec. Oligomeric A(1-42) peptide was
prepared as described previously and characterized by atomic force
microscopy (Yan et al., 2007) and mass spectrometry as reported by
Origlia et al. (2009a). Aliquots were stored at 20°C in DMSO as a
200 mM stock solution and diluted, immediately before application,
to the desired final concentration in artificial CSF (ACSF) containing the
following (in mM): 119 NaCl, 2.5 KCl, 2 CaCl2, 1.2 MgSO4 1 NaH2PO4,
6.2 NaHCO3, 10 HEPES, and 11 glucose. 4-(4-Fluorophenyl)-2-(4-
metylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580) and
anthra(1-9-cd)pyrazol-6(2H)-one (SP600125) were purchased from
Alexis; (5S)-(tert-butoxycarbonylamino)-6-phenyl-(4R)-hydroxy-(2R)-
benzylhexanoyl)-L-leucy-L-phenylalaninamide (L-685,458) was pur-
chased from Tocris Bioscience; and 2-amino-3-methoxyflavone (PD
98059) was purchased from Calbiochem. All drugs were prepared in
DMSO stock solutions (final concentration of DMSO in perfusate was
0.1%). MW108 compound was obtained from the laboratory of Dr. Wat-
terson and synthesized as reported in Watterson et al. (2013). The cell-
permeable JNK inhibitor I (L)-form was purchased from Millipore and
Interleukin-1 receptor antagonist (IL-1Ra) was purchased from Pepro-
Tech. These drugs were dissolved in sterile saline solution and then di-
luted to the desired final concentration in ACSF. Specific antibodies to
RAGE have been described in our previous studies (Yan et al., 1996).
Purified rabbit nonimmune IgG was used as a control (Bethyl).
Slice preparation. Animals were deeply anesthetized using urethane
(20% solution, 1 ml/100 g of body weight) via intraperitoneal injection
and then decapitated after disappearance of the tail pinch reflex. The
brain was rapidly removed and thick horizontal sections (400 m) con-
taining the entorhinal area were made on a Vibratome. All steps were
performed in ice-cold oxygenated ACSF solution. Before recording,
slices were stored for at least 1 h in a recovery chamber containing oxy-
genated ACSF solution at room temperature. During electrophysiologi-
cal recordings, slices were perfused at a rate of 2.5–3 ml/min with
oxygenated ACSF at 33  1°C.
Electrophysiological recordings. Extracellular field potentials (FPs) were
evoked in layer II/III in response to electrical stimulation of layer II
(Origlia et al., 2008, 2010). The amplitude of the FPs was used as a
measure of the evoked population excitatory current. All FPs had peak
latency between 4.5 and 6 ms. Baseline responses were obtained with a
stimulation intensity that yielded 50 – 60% of maximal amplitude. After
15 min of stable baseline recordings, slices were perfused for 10 min with
deoxygenated glucose-free ACSF (glucose was substituted with
D-mannitol at equimolar concentration) to obtain a transient OGD. The
amplitude of FP was monitored every 20 s and averaged every three
responses by online data acquisition software. Effects on synaptic func-
tion were evaluated either during ischemia (as the average of FP ampli-
tude during the last 3 min of 10 min OGD application) or as the recovery
of FPs calculated as the averaged relative amplitude of FPs respect to the
baseline values after reintroduction of regular ACSF (from minutes
41–50 after the end of OGD).
ELISAs. Invitrogen human A ELISA kits were used for the quantifi-
cation of A(1-42) and A(1-40) in transgenic mice tissue homogenate
following the procedure described in Chishti et al. (2001). Quantifi-
cation of phosphorylated [pTpY180/182]p38 MAPK or phosphorylated
[pTpY183/185]JNK were detected in protein extracts from slices col-
lected after electrophysiology using two different ELISA kits (Millipore).
Levels of phosphorylated forms were normalized with respect to the total
p38 MAPK and total JNK protein content that was assessed using two
ELISA kits purchased from the same company (Millipore). Quantifica-
tion of IL-1 was performed using an ELISA kit purchased from Bender
Medsystem. After electrophysiology, slices were collected, immediately
frozen at 80°C, and subsequently lysed in cell extraction buffer con-
taining the following (in mM): 10 Tris, pH 7.4, 100 NaCl, 1 EDTA, 1
EGTA, 1 NaF, 20 Na4P2O7, 2 Na3VO4, along with 1% Triton X-100, 10%
glycerol, 0.1% SDS, 0.5% deoxycholate, and 1 mM PMSF (protease mix-
ture inhibitor; Sigma-Aldrich). The extract was then centrifuged (13,000
rpm, 10 min at 4°C) to obtain a clear lysate that was used for the assay.
Statistical analysis. All data are reported as mean  SEM. Statistical
comparisons between experimental groups or between FP amplitudes
measured during baseline and after OGD protocol were performed by
applying two-way repeated-measures ANOVA with pairwise multiple-
comparison procedures (Holm–Sidak method). Comparisons between
different groups in ELISA experiments were performed using one-way
ANOVA. Differences were considered significant when p  0.05.
Results
OGD-dependent synaptic depression is enhanced in the
presence of A
Synaptic failure is the earliest consequence of ischemic brain
damage, resulting in acute and reversible or long-lasting changes
in synaptic function (Hofmeijer and van Putten, 2012).
Previous data in hippocampus and corticostriatal slices (Tozzi
et al., 2007; Medvedeva et al., 2009) showed that OGD induces
fast depression of FPs with a duration and persistence that are a
function of OGD length. As in previous work (Origlia et al., 2008,
2010), we focused our studies on the EC, an area of the brain
crucially involved in cognitive functions (Witter et al., 1989) and
affected at an early stage of AD (Braak and Braak, 1991). We
recorded FPs from superficial cortical layer II/III of EC slices after
stimulation of layer II, as described in Origlia et al. (2008). Our
results show a rapid fall of FP amplitude during 10 min OGD
(mean amplitude of the last 3 min of OGD was 32  3% of
baseline, n  11, 6 mice; Fig. 1A, vehicle-treated slices). FP am-
plitude partially recovered at the end of the OGD protocol after
reintroduction of oxygenated ACSF, reaching a stable level of
depression after 50 min (mean relative amplitude of FPs was 80 
4% of baseline, n  11 slices, 6 mice p  0.05 vs baseline; Fig. 1A,
vehicle-treated slices).
To investigate the effect of transient ischemia in an A-
enriched condition, we applied exogenously an oligomeric prep-
aration of synthetic A(1-42). When simultaneous OGD
application and A perfusion (1 M for 10 min) were used, we
observed a significant increase in long-lasting depression with
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respect to control vehicle-treated slices exposed to OGD alone
(66  4%, n  6 slices, 4 mice p  0.05; Fig. 1A); additional
control experiments were performed using the reverse peptide
A(42-1, data not shown). This synergistic effect of OGD with
A has been described previously (Mozes et al., 2012), but to
establish a causal relationship between transient ischemia and
A-dependent synaptic dysfunction, we repeated the experiment
in slices from mice expressing a mutant form of human APP
(mhAPP; Mucke et al., 2000). As reported in Figure 1B, OGD-
induced depression was significantly enhanced in mhAPP slices
(55  10%, n  10 slices, 6 mice) with respect to OGD in WT
slices (80  6.7%, n  8, 5 mice; p  0.05). To investigate
whether the different vulnerability of mhAPP slices to OGD re-
flected an increased amyloid production, we used the specific
-secretase inhibitor L-685,458 (Li et al., 2000; Parent et al.,
2005). Perfusion with this compound did not induce significant
changes in FP amplitude during baseline recordings in EC slices
(data not shown). When mhAPP slices were continuously per-
fused with 0.5 M L-685,458 (Fig. 1C),
synaptic depression was significantly
lower than in mhAPP vehicle-treated
slices either during OGD (67  11%, n 
8, 4 mice vs 40  2%, n  10 slices, 6 mice;
p  0.05) or after reoxygenation (80 
2%, n  8, 4 mice p  0.05 vs 65  10%,
n  10, 6 mice). The protective effect of
L-685,458 was not present in OGD-
treated WT slices (data not shown), sug-
gesting that its efficacy was related to
inhibition of the amyloidogenic pathway
rather than to unspecific effect on other
metabolic pathways. Furthermore, the
modulation of amyloid production by
OGD was confirmed after measurement
of A peptides in mhAPP slices collected
after electrophysiology. In EC slices that
were analyzed after 10 min of OGD, we
found an increase of A(1-42) (Fig. 1D).
Tissue level of A(1-42) after OGD was
significantly higher than that observed in
mhAPP slices not exposed to OGD
(14.6  0.7 vs 6.5  2.3 pg/mg protein,
p  0.05; n  6, 6 mice each group). Sim-
ilar results were obtained measuring
A(1– 40) levels in mhAPP EC slices tis-
sue extract (n  6; p  0.05 vs control; Fig
1D). An OGD-induced increased activity
of secretases and A production was
shown previously in cultured neuroblas-
toma cells expressing APP (T. Zhang et al.,
2014). Moreover, a modulation of A
production was reported in the hippocam-
pus 1 min after electrical stimulation (Puzzo
et al., 2011). Therefore, OGD can modulate
amyloid-metabolism and an A-enriched
environment exacerbates synaptic dysfunc-
tion after transient ischemia.
Microglial RAGE inhibition protects
against OGD-induced synaptic
dysfunction in A-enriched environment
RAGE is a multiligand membrane recep-
tor belonging to the IgG superfamily. Sev-
eral molecules released during cerebral ischemia may activate
RAGE and participate in neuronal damage, including HMGB1
(Muhammad et al., 2008), S100 (Gürsoy and Büyükuysal, 2010).
To determine whether RAGE is involved in OGD-induced de-
pression, we first examined the effect of transient ischemia in EC
slices from RAGE-null mice (RAGE KO) and in slices from WT
mice pretreated with anti-RAGE IgG (2.5 g/ml in ACSF). Pre-
vious data showed that complete RAGE inhibition by either
knocking out the RAGE gene or using blocking antibodies did
not affect basal synaptic transmission or plasticity in EC slices
(Origlia et al., 2008, 2010). The long-lasting synaptic depression
induced by OGD was not observed in presence of RAGE inhibi-
tion, because a complete recovery of FP amplitude was achieved
in slices treated with anti-RAGE IgG (100  4% of baseline, n 
6 slices, 4 mice p  0.05 vs baseline, p  0.05 vs 73  8%, n  6,
4 mice in vehicle-treated slices; Fig. 2A) and in slices from RAGE
KO mice (99  5%, n  6 slices, 4 mice p  0.05 vs baseline; p 
0.05 vs 81  4.6%, n  13, 6 mice in WT slices; Fig. 2B). These
Figure 1. OGD-dependent synaptic depression is enhanced in the presence of A. A, OGD for 10 min (corresponding to dark bar)
induced a decrease of FP amplitude in control vehicle-treated slices (open circles), reaching a stable level of depression after 50 min.
OGD-induced depression was enhanced in slices treated with A(1-42) at 1 M (gray circles) for 10 min (corresponding to dark
bar). Insets show typical traces of FP recordings before during and after OGD exposure in vehicle- and A-treated slices. B, Synaptic
depression after 10 min of OGD (dark bar) was significantly increased in mhAPP slices (gray diamonds) with respect to WT (open
circles). Insets show typical traces of FP recordings before, during, and after OGD in WT or mhAPP slices. C, OGD (dark bar, 10
min)-induced depression was significantly reduced in mhAPP slices continuously perfused with 0.5 M L-685,458 (white
squares) with respect to vehicle-treated mhAPP slices. D, Bars represent the average A(1-40) (right) and A(1-42) (left)
levels measured using an ELISA assay. Both A(1-40) and A(1-42) were significantly elevated (#p  0.05) in mhAPP
slices exposed to OGD with respect to control nonexposed mhAPP slices. Scale bars: A, B, horizontal, 5 ms; vertical, 0.5 mV.
Error bars indicate SEM.
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results confirm that RAGE is involved in the synaptic alteration
that follows transient ischemia and prompted us to investigate its
cell-specific contribution using slices from mice overexpressing a
dominant-negative form of RAGE targeted to neurons (DN-
RAGE) and to microglia (DNMSR), as described previously
(Origlia et al., 2010). Remarkably, introducing DN-RAGE in
neurons did not protect against transient ischemia (Fig. 2C) and
the effect of OGD was similar to that observed in control WT
slices (mean FP amplitude after OGD was 85  5% of baseline,
n  5, 4 mice; p  0.05 vs control WT slices after OGD). In
contrast, the effect of transient ischemia was reduced when DN-
RAGE was targeted to microglia. As shown in Figure 2C, synaptic
depression during OGD in DNMSR slices was significantly
reduced with respect to control WT (70  5%, n  9 slices, 5
mice, p  0.05 vs 33  3%, n  13 slices, 6 mice) and there was
a full recovery of FP amplitude after reintroduction of oxygen-
ated ACSF (100  6%, n  9 slices, 5 mice; p  0.05 vs control
WT). Therefore, our results indicate a different role for RAGE
in ischemia depending on its localization (neuronal vs
microglial).
Because RAGE is an A receptor that mediates synaptic plas-
ticity impairment in the hippocampus (Arancio et al., 2004) and
cortical areas (Origlia et al., 2008, 2009a, 2010), it is important to
know the role of cell-specific activation of RAGE under A load.
The A oligomers at a nanomolar concentration impair LTP-
activating RAGE expressed selectively in neurons (Origlia et al.,
2008). Interestingly, increasing synthetic A concentration up to
a micromolar level induces RAGE activation in microglial cells
that progressively affects basal synaptic transmission and LTD in
addition to LTP (Origlia et al., 2010). We therefore wanted to
confirm the protective role of specific RAGE inhibition in an
amyloid-enriched environment. First, we investigated the effect
of OGD coupled to an exogenous supply of A(1-42) (1 M for
10 min) peptide in slices from DNMSR mice. As reported in
Figure 3A, synaptic depression was reduced in DNMSR after
OGD and A exposure (mean FP amplitude  93  9%, n  6,
4 mice; p  0.05 vs 65  4%, n  8, 5 mice in WT A-treated
slices after OGD). Similarly, deficiency of RAGE in microglia was
able to contrast the effect of OGD in presence of mutant APP
overexpression. The synaptic depression was significantly lower
in slices from double-transgenic mice (mhAPPxDNMSR) with
respect to single mhAPP-transgenic slices (Fig. 3B) either during
OGD (67  11%, n  8, 4 mice vs 35  7%, n  10 slices, 6 mice;
p  0.05) or after reoxygenation (85  8%, n  8, 4 mice vs 63 
7%, n  10 slices, 6 mice; p  0.05). To investigate whether the
protective effect of DNMSR expression in mhAPP mice was due
to a modulation of A production, we repeated the measure-
ment of A(1-42) and A(1-40) in slices from mhAPPx
DNMSR mice either under basal condition or after 10 min of
OGD. The results reported in Figure 3C show that OGD in-
duced an increase of A(1-42) in mhAPPxDNMSR with re-
spect to nonstimulated slices (14.6  0.1 vs 6.48  2.6 pg/mg
protein, n  6 slices, 3 mice each group; p  0.05). A similar
result was obtained for A(1-40) levels (Fig. 3C), suggesting
that amelioration of synaptic function in mhAPPx DNMSR is
due to an inhibition of RAGE/A interaction rather than to a
reduction of A production. Therefore, our results suggest a
prominent role for RAGE expressed in microglia in the synap-
tic alterations that follow transient ischemia and also that spe-
cific molecular pathways driven by the RAGE/A interaction
contribute to exacerbate these effects.
Figure 2. Microglial RAGE contributes to OGD-induced synaptic depression. Blockade of
RAGE by either knocking out the RAGE gene or with neutralizing anti-RAGE IgG was able to
prevent ischemia-dependent long-lasting depression. FP amplitude in anti-RAGE IgG (A, gray
triangles) and RAGE-KO (B, gray squares) slices was completely rescued 50 min after OGD (10
min corresponding to dark bar) and was significantly different from FP amplitude in OGD-
exposed WT (white circles). C, RAGE-deficient signaling in neurons (DN-RAGE, gray diamonds)
was not sufficient to prevent OGD-induced synaptic depression. In contrast, DNMSR slices (c,
black triangles), characterized by RAGE signaling deficiency in microglia, displayed a significant
reduction of synaptic depression during OGD (10 min, dark bar) compared with WT (white
circles) and a full recovery of FP amplitude was achieved 50 min after. Insets show typical traces
of FP recordings before (a), during (b), and after (c) OGD in WT or DNMSR slices. Scale bars, 10 ms
(horizontal) and 1 mV (vertical). WT slices recorded in interleaved experiments were pooled
together and reported as one group in B and C. In A, vehicle control solution contained rabbit
nonimmune IgG.
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IL1 is increased during OGD and its blockade by IL1Ra
reduces synaptic dysfunction in the presence of elevated A
The results reported so far indicate a clear role for microglial
activation in the synaptic failure induced by OGD. This led us to
investigate in more detail the possible mediators that could be
released by microglia and modulate synaptic function. We and
others have demonstrated previously that IL-1 is a key molecule
that can modulate synaptic function and plasticity favoring syn-
aptic depression (Coogan et al., 1999; Ikegaya et al., 2003; Kelly et
al., 2003; Origlia et al., 2010). In particular, A mediated the
induction of IL-1 in EC slices at a concentration that is capable
of inducing synaptic dysfunction, and this effect was suppressed
in DNMSR mice (Origlia et al., 2010). To determine whether
IL1- is involved in OGD-induced depression, we investigated
the effect of transient ischemia in EC slices perfused with IL1Ra
(Fig. 4A). When slices were continuously perfused with IL1Ra (20
ng/ml), we observed a significant rescue of synaptic function dur-
ing OGD (mean amplitude  80  4%, n  6 slices, 4 mice; p 
0.05 vs 37  5%, n  8 slices, 4 mice in vehicle-treated slices
during OGD; Fig. 4A). The protective effect of the IL-1 signaling
blockade was also present after reoxygenation because FP ampli-
tude returned to the baseline values 50 min after OGD (96  5%,
n  6 slices, 4 mice p  0.05 vs baseline; p  0.05 vs 80  6%, n 
8 slices, 4 mice in vehicle-treated slices after OGD; Fig. 4A). These
results prompted us to investigate the possible protective effect of
IL1Ra in mhAPP slices exposed to transient ischemia. As shown
in Figure 4B, synaptic depression caused by OGD was signifi-
cantly reduced by IL1Ra pretreatment in mhAPP slices (during
OGD mean amplitude  67  11%, n  6 slices, 4 mice vs 39 
3%, n  9, 5 mice, and 50 min after OGD mean amplitude 
77  8%, n  6, 4 mice vs 61  7%, n  9, 5 mice in IL1Ra
mhAPP and vehicle mhAPP slices, respectively; p  0.05). Re-
markably, the involvement of IL1 was confirmed by measure-
ment of the protein levels in slices exposed to ischemia (Fig. 4C).
Using an ELISA assay, we found that IL1- tissue levels were not
significantly different between WT and 2- to 3-month-old
mhAPP slices (12.23  1.5 and 15.36  3.1 pg/ml, respectively,
n  6 slices, 4 mice each; p  0.05), in agreement with previously
reported findings (Fang et al., 2010). However, IL1 was elevated
in WT slices after 10 min of OGD with respect to nonexposed WT
slices (24.75  2.3 pg/ml, n  6, 4 mice; p  0.05). The effect of
OGD on IL-1 levels was also present in mhAPP slices (39.7 
2.9 vs 15.36  3.1 pg/ml in mhAPP slices not exposed to OGD;
n  6 slices, 4 mice, p  0.001) and was significantly enhanced
respect to that observed in OGD-exposed WT slices (24.75  2.3
pg/ml, n  6, 4 mice; p  0.001). Deficiency of RAGE signaling in
microglia (DNMSR slices) and RAGE blockade by anti-RAGE
IgG were not able to modify basal IL-1 levels (as in Origlia et al.,
2010). More importantly, RAGE blockade by anti-RAGE IgG and
deficiency of RAGE signaling in microglia (DNMSRxmhAPP)
completely prevented OGD effect, maintaining IL-1 levels com-
parable to basal values (18  3.91 and 21.7  4.8 pg/ml, respec-
tively; n  6, 4 mice; p  0.05 vs WT, p  0.05 vs mhAPP). These
results confirm that IL-1 is an inflammatory mediator that links
RAGE activation in microglia to A-induced synaptic dysfunc-
tion under ischemic conditions.
Inhibition of the stress-related kinases p38MAPK and JNK
protects against OGD-induced synaptic dysfunction in WT
and mhAPP slices
So far, our results suggested that RAGE in microglia activates an
inflammatory pathway involving IL-1 that contributes in con-
trolling synaptic responses under transient ischemia. The next
Figure 3. Microglial RAGE inhibition protects against OGD-induced synaptic dysfunction in
an A-enriched environment. A, Effect of OGD (dark bar, 10 min) coupled to exogenous supply
of A(1-42) (1 M perfused for 10 min) in slices from DNMSR mice (gray diamonds) was
significantly reduced with respect to A-treated WT slices exposed to OGD (black circles). B, A
deficiency of RAGE in microglia was able to counteract the effect of OGD in the presence of
mutant APP overexpression. The synaptic depression was significantly lower in slices from
double-transgenic mice (DNMSR  mhAPP, white circles) with respect to single mhAPP trans-
genic slices (black circles). Insets show typical traces of FP recordings before (a), during (b), and
after (c) OGD in mhAPP or mhAPPxDNMSR slices. Scale bars, 10 ms (horizontal) and 1 mV
(vertical). C, Bars represent the average A(1-40) (right) and A(1-42) (left) levels measured
using an ELISA assay. Both A(1-40) and A(1-42) were significantly elevated (*p  0.05) in
mhAPPxDNMSR slices exposed to OGD with respect to control nonexposed mhAPPxDNMSR
slices.
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step was to identify intracellular pathways associated with synap-
tic dysfunction induced by transient ischemia in an A-enriched
environment. Interestingly, the RAGE-dependent inflammatory
signaling is linked to the activation of intracellular transduction
pathways related to stress, such as p38MAPK and JNK (for re-
view, see Simm et al., 2004; Origlia et al., 2009b). Activation of
these intracellular pathways is also triggered by OGD in neurons
(Kikuchi et al., 2009; Benakis et al., 2010). In particular, a recent
study by Chen et al. (2014) demonstrated that RAGE inhibition
prevented p38MAPK phosphorylation and rescued cognitive and
synaptic plasticity deficits induced by glycated A (A-AGE).
Moreover, our previous work demonstrated that p38MAPK and
JNK activation are important key events in A-dependent syn-
aptic depression and LTD impairment (Origlia et al., 2010).
Given this evidence, we wanted to verify whether the phosphor-
ylation of p38MAPK and JNK is relevant for synaptic depression
under transient ischemia either alone or in combination with A
toxicity. At first, we used inhibitors of p38MAPK (SB203580, 1
M) and JNK (SP600125, 20 M) to prevent synaptic depression
in WT slices exposed to transient ischemia. Perfusion with either
compound did not induce significant changes in extracellular FP
amplitude during baseline recording in EC slices, in agreement
with what has been found previously (Origlia et al., 2008). As
shown in Figure 5A, continuous perfusion with SB203580 re-
duced synaptic depression during OGD (mean amplitude 
72  8% of baseline, n  6, 4 mice p  0.05 vs 34  2%, n  12,
6 mice in vehicle-treated slices) and allowed a full recovery of FP
amplitude after reoxygenation (98  3%, n  6, 4 mice p  0.05
vs baseline, p  0.05 vs 82  4% in vehicle-treated slices, n  12,
6 mice). This result was confirmed using 10 M MW-108, a novel
selective inhibitor of p38MAPK isoform (Watterson et al.,
2013) that, when perfused on slices, had a protective effect that
was comparable to that of SB203580 (mean amplitude 84  4%
of baseline during OGD and 102  2% after recovery, n  6, 4
mice; p  0.05 vs SB203580-treated slices; Fig. 5A). Synaptic
function was also ameliorated in slices continuously perfused
with SP600125 (Fig. 5B) considering both the short-term effect of
OGD (73  8% of baseline, n  7, 4 mice p  0.05 vs vehicle-
treated slices) and long-lasting depression (94  11%, n  7, 4
mice p  0.05 vs baseline, p  0.05 vs vehicle-treated slices). A
similar protection was obtained using the cell-permeable inhibi-
tor of JNK (JNKI) at 2 M (mean amplitude was 71  8% of
baseline during OGD and 101  8% after reoxygenation, n  6, 4
mice; p  0.05 vs SP600125; Fig. 5B). In contrast, when inhibition
of p42-p44 MAP kinase was investigated in OGD-exposed slices,
using the MAP kinase kinase (MEK) inhibitor PD98059 (50 M),
we did not observe any significant difference respect to control
vehicle OGD-exposed slices (mean amplitude was 26  10% of
baseline during OGD and 82  5% after reoxygenation, n  6, 4
mice; Fig. 5A). These results suggest that synaptic depression
elicited by transient ischemia is dependent on the activation of
both JNK and p38MAPK. We then investigated the effect of
p38MAPK or JNK inhibition in slices from mhAPP mice. As
reported in Figure 5, C and D, perfusion of slices throughout the
experiment with either SB203580 or SP600125 mitigated the ef-Figure 4. IL1 is increased during OGD and its blockade by IL1Ra reduces synaptic dysfunc-
tion in mhAPP slices. A, When slices were treated with 20 ng/ml IL-1Ra (gray triangles), synaptic
depression during OGD (10 min, dark bar) was significantly decreased with respect to OGD-
exposed vehicle-treated slices. In the presence of IL-1Ra (gray triangles), OGD failed to induce
long-lasting synaptic depression of FP amplitude that returned to baseline values 50 min after
transient ischemia. B, Synaptic depression caused by OGD (dark bar) was significantly reduced
by IL1Ra pretreatment in mhAPP slices (gray circles) compared with vehicle-treated mhAPP
slices (white circles). Insets show typical traces of FP recordings before (a), during (b), and after
(c) OGD in mhAPP vehicle-treated or mhAPP IL1Ra-treated slices. Scale bars, 10 ms (horizontal)
and 1 mV (vertical). C, Plot representing IL-1 levels in EC slices exposed to OGD. The basal levels
4
of IL-1 did not differ between WT and mhAPP mice (p0.05), but were significantly elevated
in WT slices exposed to OGD compared with nonexposed WT and mhAPP slices (#p  0.01). Ten
minutes of OGD induced a significantly higher level of IL-1 in mhAPP slices compared with
nonexposed mhAPP (*p  0.001) and this increase was significantly higher than that found in
WT slices exposed to OGD (*p  0.001). Error bars indicate SEM.
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fect of transient ischemia in mhAPP slices, significantly reducing
OGD-dependent depression (85  11%, n  7 slices, and 85 
9%, n  7 slices, p  0.05 vs 53  7%, n  7 in mhAPP vehicle-
treated slices). Similar to WT OGD-exposed slices, we confirmed
the specific involvement of these kinases using different inhibi-
tors (MW-108 and JNKI). As shown in Figure 5C, 10 M MW-
108 perfusion in mhAPP slices partially rescued OGD depression
in a manner comparable to the SB203580 compound (82  7%,
n  6 slices, 4 mice, p  0.05 vs SB203580 in mhAPP OGD-
exposed slices). Moreover, JNKI perfusion in mhAPP OGD-
treated slices revealed a comparable effect with respect to
SP600125 (85  7%, n  6 slices, 4 mice, p  0.05 vs SP600125 in
mhAPP OGD-exposed slices; Fig. 5D). Therefore, both
p38MAPK (in particular the  isoform)
and JNK activation are involved in synap-
tic changes induced by OGD and they
contribute to the synaptic dysfunction in-
duced by A and triggered by transient
ischemia.
OGD modulates p38MAPK and JNK
phosphorylation differently in WT and
mhAPP cortical slices
To better clarify whether the phosphory-
lation of stress-related kinases follows
cell-specific RAGE activation after tran-
sient ischemia, we measured tissue levels
of phosphorylated p38MAPK and phos-
phorylated JNK in EC slices that were col-
lected after the end of electrophysiology.
WT slices that were exposed to 10 min of
OGD showed a significant increase in
phospho-p38MAPK tissue levels with re-
spect to nonexposed WT slices (141.75 
27 U/ng vs 32.33  19.8 U/ng, n  6; p 
0.01; Fig. 6A). As reported previously
(Origlia et al., 2010), selective deficiency
of RAGE signaling in microglia (DNMSR)
or complete inactivation of RAGE (anti-
RAGE IgG) did not modify the basal level
of phospho-p38MAPK (data not shown).
However, slices either from DNMSR mice
or WT mice treated with anti-RAGE IgG
displayed complete suppression of
phospho-p38MAPK after OGD (20.86 
5 U/ng and 51.6  14 U/ng, respectively,
n  6; p  0.05 vs WT exposed to OGD
and p  0.05 vs control WT slices; Fig.
6A). The p38MAPK activation that follows
OGD was even more robust in mhAPP
slices. After OGD, tissue phospho-p38 levels
were enhanced in mhAPP with respect to
nonexposed mhAPP slices (418.22  65
U/ng and 55.167.7 U/ng respectively, n
6; p  0.001; Fig. 6A) and significantly
higher with respect to those found in OGD-
exposed WT slices (p  0.001). Like WT, in
mhAPP slices, selective deficiency of RAGE
signaling in microglia or RAGE inhibition
with specific IgG were capable of preventing
p38MAPK phosphorylation after OGD
(30.39  11.7 U/ng and 58.2  25.9 U/ng in
DNMSR  mhAPP and anti-RAGE IgG
treated slices, respectively, n  6; p  0.001 vs mhAPP OGD-
exposed slices; p  0.05 vs mhAPP nonexposed slices). Interestingly,
the pharmacological inhibition of the other stress-related kinase
(JNK) abolished the effect of OGD in either WT or mhAPP slices.
Indeed, in presence of SP600125 phospho-p38MAPK after OGD
returned to baseline levels both in WT (22.43  2.8 U/ng, n  6; p 
0.01 vs WT OGD exposed slices; p  0.05 vs WT nonexposed slices)
and mhAPP slices (29.51  9.18, n  6; p  0.001 vs mhAPP after
OGD; p  0.05 vs mhAPP without OGD exposure). To further
explore the molecular link between kinase activation and IL-1 re-
lease, we measured phospho-p38MAPK levels in slices treated with
IL-1Ra. As shown in Figure 6A, IL1Ra was not capable of preventing
the increase of phospho-p38MAPK after OGD either in WT (110 
Figure 5. OGD-induced synaptic dysfunction in WT and mhAPP slices is prevented by inhibition of the stress-related kinases
p38MAPK and JNK. A, Treatment of slices with either 1 M SB203580 (gray squares) or 10 M MW-108 (filled triangles) was able
to reduce synaptic depression during OGD (dark bar) and allowed a full recovery of FPs 50 min after transient ischemia. In contrast,
the MEK inhibitor PD 98059 (50 M, gray diamonds) did not affect OGD-dependent depression. B, A similar protective effect was
achieved in slices after treatment with either 20 M SP600125 (black triangles) or JNKI (filled triangles). C, In mhAPP slices,
the OGD-induced depression was significantly diminished by SB203580 (gray squares) or MW-108 (black circles) compared
with vehicle-treated mhAPP slices (white circles). D, SP600125 (black triangles) and JNKI (black circles) were capable of
reducing OGD-induced depression in mhAPP slices compared with vehicle-treated mhAPP slices (white circles). The insets
in A–D represent typical traces of FP recordings before (a), during (b), and after (c) OGD. Scale bars, 5 ms (horizontal) and
1 mV (vertical).
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35 U/ng; n  6; p  0.05 vs WT nonexposed
slices; p  0.05 vs WT OGD exposed slices)
or in mhAPP slices (370  63.4 U/ng; n  6;
p  0.001 vs mhAPP nonexposed slices; p 
0.05 vs mhAPP slices after OGD), suggest-
ing that p38MAPK activation represents an
upstream event with respect to IL-1 re-
lease. These data confirm that p38MAPK is
strongly activated during transient ischemia
in cortical slices overexpressing mutant hu-
man APP, and this phenomenon is specifi-
cally driven by RAGE expressed in microglia
and requiring JNK phosphorylation.
Similarly, we measured JNK phos-
phorylation levels after OGD exposure in
EC slices from either WT or mhAPP mice
(Fig. 6B). Slice perfusion with ischemic
solution for 10 min significantly increased
the JNK phosphorylation compared with
the vehicle-treated slices (15.47  3.8 vs
6.53  0.4 U/ng, n  6; p  0.05). How-
ever, different from p38MAPK, the acti-
vation of JNK was not prevented in
DNMSR slices and in slices pretreated
with anti-RAGE IgG (15.04  1.45 U/ng
and 16.38  2.2, n  6; p  0.05 vs control
WT nonexposed slices; p  0.05 vs Wt
OGD-exposed slices). Therefore, JNK
phosphorylation in cortical slices after
OGD is independent from RAGE signal-
ing. A different result emerged when we
examined the effect of OGD on JNK phos-
phorylation in mhAPP slices. Levels of
phospho-JNK were elevated after OGD
with respect to nonexposed mhAPP
slices (11.82  1.45 U/ng vs 6.02  1.6
U/ng, n  6, p  0.05), but in this case,
genetic inhibition of RAGE in microglia
(DNMSR  mhAPP) or anti-RAGE
blocking IgG were able to maintain basal
values of phospho JNK after OGD (5.17 
0.9 and 7  1.56 U/ng, respectively, n  6;
p  0.05 vs mhAPP exposed to OGD; p 
0.05 vs mhAPP not exposed to OGD).
Therefore, in the presence of mhAPP
overexpression, JNK activation under
transient ischemia is specifically con-
trolled by microglial RAGE. Finally, to
complete the analysis of stress-related signaling pathways in-
volved in OGD-induced synaptic dysfunction, we measured JNK
activation in WT and mhAPP slices treated with SB203580 and
IL1Ra. Consistently with the results for p38MAPK, IL1Ra was not
able to prevent JNK activation after OGD either in WT (14.79 
0.9 U/ng, n  6; p  0.05 vs WT not exposed to OGD) or in
mhAPP cortical slices (14.53  2 U/ng, n  6; p  0.05 vs mhAPP
not exposed to OGD), confirming that the JNK pathway is up-
stream with respect to IL-1 signaling. In contrast, pharmacolog-
ical inhibition of p38MAPK with SB203580 completely
prevented OGD-induced activation of JNK in WT (4.86  1.89
U/ng, n  6; p  0.05 vs WT after OGD) and in mhAPP (6.39 
0.1 U/ng, n  6; p  0.05 vs mhAPP exposed to OGD). These
results confirm that, after transient ischemia and in the presence
of mhAPP overexpression, a cell-specific RAGE signaling in-
volves the phosphorylation of JNK and p38MAPK that are prob-
ably coactivated and reciprocally required to induce synaptic
depression.
Discussion
The present study focused on RAGE as a key molecule that me-
diates the effect of transient ischemia on synaptic function. Pre-
vious results have linked RAGE to brain ischemia. In particular, it
has been shown that RAGE mediates ischemic damage in an in
vivo model of medial cerebral artery occlusion (MCAO), contrib-
uting to neuroinflammation (Muhammad et al., 2008) and mod-
ulating the severity of injury (Hassid et al., 2009). In addition,
RAGE expression is modulated by the Hypoxia-inducible Factor-
1- (HIF-1), a transcription factor activated during ischemia
(Pichiule et al., 2007). Here, using an in vitro model of glucose/
Figure 6. OGD increases p38MAPK/JNK phosphorylation in WT and mhAPP cortical slices. A, Plot representing averaged
phospho-p38MAPK levels measured using ELISA and expressed as units per total content of p38MAPK protein. In WT slices, tissue
levels of phospho-p38MAPK after 10 min of OGD were significantly higher with respect to control vehicle-treated slices (left, *p 
0.01). Selective deficiency of RAGE signaling in microglia (DNMSR) and complete inactivation of RAGE with anti-RAGE IgG was able
to prevent the OGD-induced increase of phospho-p38MAPK (left, p 0.05 vs WT OGD-exposed slices). p38MAPK activation by OGD
was also reduced in presence of JNK inhibition (left, SP600125, p  0.05 vs OGD-exposed WT slices), but not by treatment with
IL-1Ra (left, *p  0.05 vs WT control slices). A robust increase in phospho-p38MAPK was also observed in mhAPP slices after OGD
(right, °p  0.001 vs non-OGD mhAPP) and this increase was prevented in double-transgenic DNMSRxmhAPP or in anti-RAGE
IgG-treated mhAPP slices (right, p  0.05 vs non-OGD mhAPP slices). In mhAPP slices, JNK inhibition (right, SP600125) was
effective in reducing p38MAPK activation, whereas phosphor-p38 was still elevated after IL-1Ra treatment (right, °p  0.001 vs
non-OGD mhAPP slices). B, Plot representing averaged phospho-JNK levels measured using ELISA and expressed as units/total
content of JNK protein. Tissue levels of phospho-JNK were elevated after 10 min of OGD in WT cortical slices (left, *p  0.05 vs WT
nonexposed slices). Inhibition of RAGE (in DNMSR or anti-RAGE IgG-treated slices) or blockade of IL-1 signaling with IL-1Ra did
not reduce the OGD effect (left, *p  0.05 vs WT nonexposed slices), whereas inhibition of p38MAPK (SB203580) significantly
reduced JNK activation by OGD (left, p0.05 vs WT nonexposed slices). A similar increase of JNK activation was observed in mhAPP
slices exposed to OGD (right, °p  0.05 vs mhAPP nonexposed slices). Blockade of RAGE by IgG or inhibition of RAGE in microglia in
double-transgenic DNMSRxmhAPP mice suppressed OGD-induced increase of phospho-JNK (right, p  0.05 vs nonexposed
mhAPP slices). Basal levels of phospho-JNK were also maintained in mhAPP slices exposed to OGD that were treated with p38MAPK
inhibitor (right, SB203580, p  0.05 vs nonexposed mhAPP slices), whereas phospho-JNK was still activated in mhAPP slices
treated with IL-1Ra and exposed to OGD (°p  0.05 vs mhAPP nonexposed slices). Error bars indicate SEM.
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oxygen deprivation and genetic inhibition of RAGE, we provide
evidence that this receptor, and particularly its expression on
microglial cells, can modulate an inflammatory pathway control-
ling synaptic function during transient ischemia. However, acti-
vation of RAGE signaling during ischemia can lead to deleterious
or beneficial consequences. In particular, overexpression of neu-
ronal RAGE renders the brain more vulnerable to ischemia/rep-
erfusion injury (Hassid et al., 2009), whereas another study
demonstrated that inhibition of RAGE signaling resulted in neu-
roprotection (Pichiule et al., 2007). Our present work partially
confirmed this dual role for RAGE because brain slices were pro-
tected against an OGD effect on synaptic function either by com-
plete inhibition (RAGE KO or anti-RAGE IgG) or selective
inhibition of RAGE in microglia (DNMSR), but not in slices with
deficient RAGE signaling in neurons. One possible explanation
for this difference is the diversity of ligands that may interact with
RAGE, triggering specific intracellular pathways and the localiza-
tion of RAGE expression in different cell types. Indeed, a search
for ligands capable of binding RAGE resulted in an array of mol-
ecules; for example, other than the AGEs (advanced glycation
end-products), RAGE binds high mobility group (HMG) pro-
teins, including HMGB1 (also known as amphoterin), S100/cal-
granulin, and -amyloid. The protective anti-inflammatory
effect of HMGB1 antagonism at the receptor RAGE has been
demonstrated in an in vivo model of brain ischemia and con-
firmed in vitro, when RAGE expression in microglial cells medi-
ated the toxic effect of HMGB1 (Muhammad et al., 2008).
Conversely, treatment of neurons with low concentrations of
S100B decreased neuronal death after OGD and this effect was
abolished by a neutralizing antibody against RAGE. Conversely,
high concentrations of exogenous S100B had a cytotoxic effect
that was RAGE independent (Pichiule et al., 2007). Furthermore,
some experimental evidence has demonstrated a clear role for the
A protein in the development of neuronal injury under isch-
emic conditions (for review, see Pluta et al., 2013). It is important
to note that hypoxia upregulates APP cleaving enzymes such as
BACE1 (-site APP cleaving enzyme) and -secretase, resulting
in A overproduction (Tanimukai et al., 1998; Pennypacker et
al., 1999; Sun et al., 2006; Zhang et al.,
2007; Guglielmotto et al., 2009; Li et al.,
2010; Zhiyou et al., 2009) and an in-
creased risk of AD development. The link
between A protein accumulation and
ischemia has been strengthened by obser-
vations in AD mouse models carrying ei-
ther single (Zhang et al., 1997) or double
(Kitaguchi et al., 2009) APP mutations.
Conversely, suppression of the WT pro-
tein in APP knock-out mice increased the
risk of mortality as a result of cerebral
ischemia (Koike et al., 2012); accordingly,
overexpression of WT APP provides neu-
roprotection after MCAO in rats (Clarke
et al., 2007). This evidence suggests that,
when expressed normally, APP might be a
stress response protein that is beneficial in
a hypoxic/ischemic environment; how-
ever, it becomes detrimental when it is ab-
normally processed to form toxic A
peptides. In agreement with this hypoth-
esis, our experiments demonstrate that
the OGD effect on synaptic function is
worsened in the presence of elevated A
or in an environment that is prone to overproducing A, such as
in slices from mhAPP mice. An additional important finding in
mhAPP mice was that A levels were increased after OGD and
that by inhibiting -secretase, we were able to ameliorate synaptic
function.
Previous reports showed that RAGE is implicated in disrup-
tion of synaptic function by A (Arancio et al., 2004; Origlia et al.,
2008). In the EC, nanomolar oligomeric A inhibits LTP through
activation of RAGE in neurons (Origlia et al., 2008), whereas
microglial RAGE contributes to synaptic depression and LTD
impairment induced by higher concentrations of A (Origlia et
al., 2010). In the present study, we investigated the cell-specific
A/RAGE signaling that is triggered by ischemia and lead to syn-
aptic depression. The important finding was that selective inhi-
bition of RAGE in microglial cells was able to mitigate the effect of
OGD, ameliorating synaptic function. This result is in agreement
with previous observations that microglial RAGE plays a key role
in the development of inflammatory response and cellular dys-
function in an A milieu (Du Yan et al., 1997; Lue et al., 2001;
Fang et al., 2010) and raise the important issue of identifying the
mediators released by stimulated microglial cells on exposure to
OGD that are capable of interacting with neurons. The activation
of RAGE in microglia enhances production of proinflammatory
cytokines such as IL-1 and TNF- (Lue et al., 2001; for review,
see Simm et al., 2004; Chen et al., 2007; Fang et al., 2010). Impor-
tantly, IL-1 is implicated in disruption of synaptic efficacy in-
duced by proinflammatory agents (Curran et al., 2003; Kelly et
al., 2003) and is capable of inducing synaptic depression in the
hippocampus (Ikegaya et al., 2003). In our previous work, we
confirmed that IL-1 perfusion on EC slices causes a depression
of FP amplitude that can persist after the washout. Moreover, we
demonstrated that A/RAGE signaling in microglia mediated the
induction of IL-1 in EC slices (Origlia et al., 2010). Consistent
with a previous work in the hippocampus (Yoshioka et al., 1999),
our present data demonstrated that IL-1 is involved in synaptic
impairment induced by OGD that can be prevented by IL-1Ra.
More importantly, IL-1 antagonism was effective in ameliorating
synaptic function in OGD-exposed mhAPP slices, in which IL-1
Figure 7. Schematic drawing representing the interaction of neurons and microglia that is triggered by OGD in an amyloid-
enriched environment. An ischemic insult enhances the deleterious effect of amyloid on synaptic function. Amyloid overproduction
induced by OGD leads to RAGE engagement in microglia and activation of p38mapk and JNK. The kinases, in turn, control the
release of proinflammatory cytokines such as IL-1, which may affect synaptic function. This is a self-maintained loop that
amplifies the effect of A and shift synaptic activity toward depression.
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elevation was particularly evident. This effect was RAGE specific,
because functional inactivation of the receptor or deficiency of
RAGE signaling in microglia significantly suppressed OGD-
induced IL-1 production. Therefore, A/RAGE signaling in mi-
croglia under an ischemic insult controls the release of IL-1 that
can exert its effect on neurons, causing synaptic depression.
To gain further insight in to the intracellular signaling cas-
cade(s) that might be activated by A-RAGE interaction during
OGD, leading to IL-1 release, we investigated the role of
p38MAPK and JNK. We focused our attention to these kinases
because they are involved in the cellular response to OGD (Shi-
nozaki et al., 2007; Guglielmotto et al., 2009; Liu et al., 2011) and
because they are strongly activated in EC slices exposed to high
levels of A (Takuma et al., 2005; Origlia et al., 2008, 2010). We
found that OGD induced the phosphorylation of p38MAPK and
that this effect was enhanced in mhAPP slices. In agreement with
our hypothesis, p38MAPK activation was reduced by RAGE in-
hibition in microglia, but not in the presence of IL-1 antago-
nism. Interestingly, when ischemia was applied to WT slices, the
phosphorylation of the other kinase, JNK, was independent from
RAGE because it was not prevented by functional or genetic in-
hibition of the receptor. This result could be the consequence of
an early direct activation of JNK induced by hypoxia via oxidative
stress (Tamagno et al., 2008, 2009; Guglielmotto et al., 2009). In
contrast, the increase of phospho-JNK was predominantly con-
trolled by microglial RAGE in mhAPP mice, confirming that in
presence of elevated A, a specific inflammatory pathway, is
stimulated during OGD, contributing to synaptic dysfunction.
This result is consistent with the robust activation of JNK induced
by A that has been described previously (Shoji et al., 2000; Mor-
ishima et al., 2001; Troy et al., 2001; Jang and Surh, 2002; Wei et
al., 2002; Fogarty et al., 2003; Minogue et al., 2003, Origlia et al.,
2010). However, regardless of A, the JNK activation was up-
stream of IL-1 release because it was not inhibited by IL-1Ra.
Finally, we demonstrated that specific inhibition of only one of
the two kinases using SB203580 or SP600125 was sufficient to
prevent the activation of the other and to prevent synaptic de-
pression. Therefore, p38MAPK and JNK coactivation is an im-
portant key event required for A-mediated synaptic depression
that is triggered by OGD. Together, our results suggest that in
A-enriched conditions, the stimulation of RAGE in microglial
cells leads to the simultaneous activation of JNK and p38MAPK.
These kinases are capable of modulating IL-1 release, which
affects neuronal function, inducing synaptic depression (Fig. 7).
Microglial cells were shown to be critically involved in plastic
changes associated with either physiological (Wake et al., 2009)
or pathological (for review, see Kettenmann et al., 2013) condi-
tions. In particular, the amyloid-dependent LTP blockade in hip-
pocampus was prevented by microglia inhibition (Wang et al.,
2004b). More recently, a specific role for microglia in synaptic
depression induced by hypoxia has emerged (J. Zhang et al.,
2014). In that study, the combination of hypoxia and an inflam-
matory stimulus (LPS) was shown to trigger a long-term form of
synaptic depression with a mechanism that requires microglial
CR3 receptor. In addition, LPS  hypoxia LTD was caused by
AMPA receptor endocytosis (J. Zhang et al., 2014). Furthermore,
elevated extracellular A causes synaptic depression, negatively
modulating AMPA-mediated currents and inducing AMPA re-
ceptor endocytosis with a mechanism dependent on p38MAPK
activation (Hsieh et al., 2006; Origlia et al., 2010). This is some-
what consistent with our present findings, which demonstrate a
synergistic effect of A and OGD capable of inducing a similar
form of LTD that is dependent on RAGE signaling in microglial
cells and on activation of cell-stress kinases.
Some clinical and experimental evidence supports the hy-
pothesis that transient ischemic episodes may accelerate A-
dependent synaptic dysfunction, leading to cognitive impairment and
development of AD pathology (De la Torre, 2005, 2008; Gorelick
et al., 2011; Pimentel-Coelho et al., 2013; for review, see Pluta et
al., 2013). In view of this, our present study suggests that the
inflammatory pathway driven by the RAGE/A interaction may
represent a basic mechanism that links vascular pathology to AD.
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